Latest news and press releases about Trevi Therapeutics, Inc. (TRVI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis.
Price
| Price | $15.01 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 7.33 |
| EV / EBITDA | -40.70 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -23.59% |
| Return on Invested Capital | -18.46% |
| Return on Assets | -15.46% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARDX · NVAX · ORIC · PGEN · TERN · TRML · UPB
Explore sector: Healthcare · Biotechnology
More sections of TRVI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks